An assay for long-term engrafting human hematopoietic cells based on newborn NOD/SCID/β2-microglobulinnull mice

Ishikawa, Fumihiko; Livingston, Anne G.; Wingard, John R.; Nishikawa, Shin Ichi; Ogawa, Makio

doi:10.1016/s0301-472x(02)00784-1

Cited by 51 publications

(50 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[4][5][6] We tested this controversy by using our recently developed assay based on newborn NOD/SCID/ BMG null mice. 9 Our results indicated that CB CD34 + cells have more than 100-fold higher engraftment capability than CB CD34 À cells at 4-5 months post-transplantation. Also, secondary reconstitution capability existed exclusively in the CD34 + population.…”

Section: Figurementioning

confidence: 55%

“…Newborn NOD/SCID/BMG null mice were conditioned with 37 mg/kg of 5-fluorouracil (5 FU, 50 mg/ml, Pharmacia & Upjohn, Kalamazoo, MI, USA) and 30 mg/kg of blocking anti-mouse c-kit antibody, Ack-2, as described previously. 9 Isolated human CB cells were injected through the facial vein of newborn mice 24 h after the conditioning.…”

Section: Transplantationmentioning

confidence: 99%

“…To elucidate this controversy, we examined long-term reconstituting capability of human CB CD34 + and CD34 -cells by using our newly developed assay. 9 After CB MNCs were depleted of T cells, the samples were separated into two populations based on the expression of CD34 with the use of Miltenyi microbeads. The purity of CD34 + cells was higher than 99.9% and that of CD34 À population higher than 95% (Figure 1).…”

Section: Engraftment Capability Of Cd34 + Cells and Cd34 à Cellsmentioning

confidence: 99%

“…Recipient mice were analyzed for engraftment at 4-5 months post-transplantation. 9 The mice transplanted with CD34 À cells showed less than 1% or no human cells (Figure 2). In contrast, the mice transplanted with CD34 + cells showed engraftment at the levels of 27.7718.6% (Figure 2).…”

Section: Engraftment Capability Of Cd34 + Cells and Cd34 à Cellsmentioning

confidence: 99%

“…This allows the observation period of engraftment to be extended to 4-5 months. Additionally, we used NOD/SCID/b2-microglobulin-null (NOD/SCID/BMG null ) mice, 9 which support higher levels of xenogeneic engraftment than other conventional immune incompetent recipients. 10,11 Using this assay, the 34 + and 34 À populations of CB cells were analyzed at 4-5 months post-transplantation.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Human cord blood long-term engrafting cells are CD34+ CD38−

et al. 2003

View full text Add to dashboard Cite

There have been controversies about CD34 and CD38 expression by human cord blood (CB) stem cells. Using the newborn NOD/SCID/b2-microglobulin-null mouse assay that we recently developed, we examined the in vivo engrafting capability of human CB cells. Almost all of the 4-5 months engrafting cells were found in CD34 + population. The capability of secondary reconstitution was found only in the CD34 + cells. When the CD34 + CB cells were separated into CD38 À and CD38 + subpopulations and tested for engraftment, the majority of the engrafting cells were detected in the CD38 À subpopulation. These findings are consistent with the results from studies of murine stem cells and strongly indicate that the phenotype of human CB stem cells is CD34 + CD38 À . Leukemia (2003) 17, 960-964.

show abstract

Section: Figurementioning

confidence: 55%

Section: Transplantationmentioning

confidence: 99%

Section: Engraftment Capability Of Cd34 + Cells and Cd34 à Cellsmentioning

confidence: 99%

Section: Engraftment Capability Of Cd34 + Cells and Cd34 à Cellsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Human cord blood long-term engrafting cells are CD34+ CD38−

et al. 2003

View full text Add to dashboard Cite

show abstract

Hematopoietic stem cells

Bonnet

2003

Birth Defects Research Pt C

View full text Add to dashboard Cite

Considerable effort has been made in recent years in defining the embryonic origin of the hematopoietic stem cell (HSC). Using transgenic mouse models, a number of genes that regulate the formation, self-renewal, or differentiation of HSCs have been identified. Of particular interest, it has recently been shown that key regulators of definitive blood formation played a crucial role in adult HSC development. Specifically, the use of some of these regulatory molecules has dramatically improved the potential of adult HSC expansion. Furthermore, the elucidation of the molecular phenotype of the HSC has just begun. Finally, unexpected degrees of HSC developmental or differentiation plasticity have emerged. In this review, we will summarize the recent advances made in the human HSC field, and we will examine the impacts these discoveries may have clinically and on our understanding of the organization of the human hematopoietic system.

show abstract

Production of Humanized Mice Through Stem Cell Transfer

Huey

Niewiesk

2018

CP Mouse Biology

View full text Add to dashboard Cite

The development of humanized mice has become a prominent tool for translational animal studies of human diseases. Here we show how immune deficient mice can be "humanized" by injections of human umbilical cord stem cells. The engraftment of these cells and development into human lymphocytes has been possible because of the development of novel severely immune deficient mouse strains. Here we present proven protocols for the generation and analysis of humanized mice on the NSG mouse background.

show abstract

An assay for long-term engrafting human hematopoietic cells based on newborn NOD/SCID/β2-microglobulinnull mice

Cited by 51 publications

References 20 publications

Human cord blood long-term engrafting cells are CD34+ CD38−

Human cord blood long-term engrafting cells are CD34+ CD38−

Hematopoietic stem cells

Production of Humanized Mice Through Stem Cell Transfer

Contact Info

Product

Resources

About